• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients.非霍奇金淋巴瘤患者临床试验理解的年龄差异。
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e549-e554. doi: 10.1016/j.clml.2022.02.003. Epub 2022 Feb 22.
2
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗:用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
3
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.自体造血干细胞移植治疗复发/难治性非霍奇金淋巴瘤患儿、青少年及青年患者的特征和结局。
BMC Cancer. 2023 Dec 20;23(1):1258. doi: 10.1186/s12885-023-11712-6.
4
Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.活动性监测中惰性非霍奇金淋巴瘤和慢性淋巴细胞白血病患者生活质量恶化:一项为期 12 个月的纵向研究。
Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):82-88. doi: 10.1016/j.clml.2021.08.001. Epub 2021 Aug 12.
5
Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.老年侵袭性非霍奇金淋巴瘤患者的临床结局、治疗毒性和医疗保健利用情况。
Oncologist. 2021 Nov;26(11):965-973. doi: 10.1002/onco.13915. Epub 2021 Aug 12.
6
Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study.非霍奇金淋巴瘤幸存者的精液质量:一项单中心回顾性研究。
Hum Reprod. 2021 Jan 1;36(1):16-25. doi: 10.1093/humrep/deaa266.
7
Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: a systematic review.纳入老年非霍奇金淋巴瘤随机对照临床试验的障碍:系统评价。
Cancer Treat Rev. 2013 Nov;39(7):812-7. doi: 10.1016/j.ctrv.2013.01.007. Epub 2013 Mar 6.
8
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).新型药物在老年慢性淋巴细胞白血病和非霍奇金淋巴瘤患者中导致三级或四级毒性的频率和影响(alliance A151611)。
J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.
9
Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience.
Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):464-71. doi: 10.1016/j.clml.2015.02.025. Epub 2015 Mar 5.
10
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.Copanlisib 联合利妥昔单抗与安慰剂联合利妥昔单抗治疗复发惰性非霍奇金淋巴瘤(CHRONOS-3):一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Oncol. 2021 May;22(5):678-689. doi: 10.1016/S1470-2045(21)00145-5. Epub 2021 Apr 10.

引用本文的文献

1
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis.滤泡性淋巴瘤患者的真实世界治疗模式与临床结局:一项监测、流行病学和最终结果数据库(SEER)与医疗保险数据分析
Blood Neoplasia. 2025 Feb 21;2(2):100080. doi: 10.1016/j.bneo.2025.100080. eCollection 2025 May.
2
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.评估滤泡性淋巴瘤一线临床试验入选标准的影响:MER/LEO 队列分析。
Blood Adv. 2022 Aug 9;6(15):4413-4423. doi: 10.1182/bloodadvances.2022007687.

本文引用的文献

1
Clinical trial participation assessed by age, sex, race, ethnicity, and socioeconomic status.按年龄、性别、种族、民族和社会经济地位评估临床试验参与情况。
Contemp Clin Trials. 2021 Apr;103:106315. doi: 10.1016/j.cct.2021.106315. Epub 2021 Feb 21.
2
Association of Age at Cancer Diagnosis and Clinical Trial Participation.癌症诊断年龄与临床试验参与的关联。
JAMA Netw Open. 2021 Feb 1;4(2):e2037573. doi: 10.1001/jamanetworkopen.2020.37573.
3
Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063.卡尔·B·S、杨·D·T。滤泡性淋巴瘤:不断演变的治疗策略。《血液》。2016年;127(17):2055 - 2063。
Blood. 2016 Jul 21;128(3):463. doi: 10.1182/blood-2016-06-721902.
4
Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.与癌症临床试验参与者年龄差异相关的因素。
JAMA Oncol. 2019 Dec 1;5(12):1769-1773. doi: 10.1001/jamaoncol.2019.2055.
5
A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.利益相关者驱动的方法改进姑息化疗的知情同意过程。
Patient Educ Couns. 2017 Aug;100(8):1527-1536. doi: 10.1016/j.pec.2017.03.024. Epub 2017 Mar 22.
6
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.临床试验参与在癌症研究中的作用:障碍、证据与策略
Am Soc Clin Oncol Educ Book. 2016;35:185-98. doi: 10.1200/EDBK_156686.
7
Cancer clinical trial participants' assessment of risk and benefit.癌症临床试验参与者对风险与益处的评估。
AJOB Empir Bioeth. 2016;7(1):8-16. doi: 10.1080/23294515.2015.1034381. Epub 2015 May 1.
8
The Relationship of Health Literacy With Use of Digital Technology for Health Information: Implications for Public Health Practice.健康素养与健康信息数字技术使用之间的关系:对公共卫生实践的启示。
J Public Health Manag Pract. 2017 Jul/Aug;23(4):380-387. doi: 10.1097/PHH.0000000000000366.
9
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.提高癌症老年患者治疗证据基础:美国临床肿瘤学会声明。
J Clin Oncol. 2015 Nov 10;33(32):3826-33. doi: 10.1200/JCO.2015.63.0319. Epub 2015 Jul 20.
10
Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.试验招募失败与人体受试者保护:对近期结束试验的实证分析
Clin Trials. 2015 Feb;12(1):77-83. doi: 10.1177/1740774514558307. Epub 2014 Dec 4.

非霍奇金淋巴瘤患者临床试验理解的年龄差异。

Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients.

机构信息

Weill Cornell Medicine, New York, NY; NewYork-Presbyterian Hospital, New York, NY.

Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e549-e554. doi: 10.1016/j.clml.2022.02.003. Epub 2022 Feb 22.

DOI:10.1016/j.clml.2022.02.003
PMID:35307317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9232921/
Abstract

BACKGROUND

Clinical trials are often an important component of cancer care but are misunderstood by many patients. Few studies have examined age differences in clinical trial understanding in older versus younger adults, especially among patients with indolent non-Hodgkin lymphoma (NHL), a slowly progressive and not typically curable cancer diagnosed primarily in older adults.

PATIENTS AND METHODS

Participants aged ≥21 years with a diagnosis of NHL were recruited from a single academic medical center in an urban setting. Age was dichotomized as <65 and ≥65 years. Clinical trial understanding was assessed using a four-item survey of potential goals of a clinical trial, with responses including "yes," "no," and "I don't know." Survey responses were examined by age using Chi-square tests.

RESULTS

The sample was comprised of 74 patients who were predominantly non-Latino White, with a mean age of 60.4 years (SD = 12.27). Compared to younger patients, older patients were more likely to respond "I don't know" to the clinical trial goals of reducing the lymphoma (41.4% vs. 13.3%; P = .023) and keeping the lymphoma from worsening (41.4% vs. 13.3%; P = .017). Age differences for the remaining goals were not statistically significant. Similar findings emerged when the sample was restricted to patients under active surveillance.

CONCLUSION

Relative to younger adults, older adults may have a less nuanced understanding of clinical trial goals. Therefore, older adults may benefit from developmentally-tailored interventions to improve clinical trial understanding. Future research should examine the relationship between clinical trial understanding and enrollment by age using validated measures in diverse samples.

摘要

背景

临床试验通常是癌症治疗的重要组成部分,但许多患者对此存在误解。很少有研究调查过年龄对临床试验理解的影响,尤其是在年龄较大的非霍奇金淋巴瘤(NHL)患者中,这种癌症进展缓慢,通常无法治愈,主要在老年人中诊断。

患者和方法

在一个城市环境中的一家学术医学中心招募了年龄≥21 岁且患有 NHL 的参与者。年龄分为<65 岁和≥65 岁。使用一个包含四项潜在临床试验目标的调查评估临床试验理解程度,回答选项包括“是”、“否”和“不知道”。使用卡方检验按年龄分析调查回答。

结果

样本由 74 名患者组成,他们主要是非拉丁裔白人,平均年龄为 60.4 岁(SD=12.27)。与年轻患者相比,年长患者对减少淋巴瘤(41.4%比 13.3%;P=.023)和防止淋巴瘤恶化(41.4%比 13.3%;P=.017)这两个临床试验目标回答“不知道”的可能性更高。对于其余目标,年龄差异没有统计学意义。当将样本限制在正在接受主动监测的患者中时,也出现了类似的发现。

结论

与年轻成年人相比,年长成年人可能对临床试验目标的理解不够细致。因此,年长成年人可能受益于为提高临床试验理解而量身定制的发展干预措施。未来的研究应该使用验证过的方法在不同的样本中检查临床试验理解程度与年龄之间的关系。